Desentum on suomalainen, tutkimuslähtöinen biolääkeyritys, joka kehittää uudentyyppisiä tuott
Location: Finland, Mainland Finland, Helsinki
Employees: 11-50
Total raised: $22.04M
Founded date: 2011
Investors 1
| Date | Name | Website |
| - | Cascara ve... | cascaraven... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 20.02.2024 | - | $12.97M | - |
| 21.01.2022 | - | $9.07M | - |
Mentions in press and media 6
| Date | Title | Description |
| 20.02.2024 | Finland’s Desentum raises €12M to advance allergy vaccine development | Finland’s Desentum raises €12M to advance allergy vaccine development 20 February, 2024, 17:11 Rostyslav Sobachynskyi --> --> --> -->--> --> --> --> --> --> --> --> --> Desentum, a Finnish biopharma... |
| 20.02.2024 | Finland’s Desentum bags €12M to boost allergy vaccine development | Read this article in: Espoo-based Desentum, a biopharmaceutical company, announced that it has raised €12M in a fresh funding round to continue the clinical development of the birch pollen allergy vaccine. The company’s lead product candida... |
| 21.01.2022 | Finland’s Desentum raises €8M to develop novel types of allergen immunotherapy products | Allergy is one of the most common chronic conditions in Europe. Currently, over 150 million Europeans suffer from allergic diseases. The European Academy of Allergy and Clinical Immunology (EAACI) predicts that by 2025, allergy will affect ... |
| 21.01.2022 | Desentum raised 8 M€ to advance clinical development of lead allergy vaccine candidate | Desentum raised 8 M€ to advance clinical development of lead allergy vaccine candidate Fri, Jan 21, 2022 08:00 CET Finnish biopharmaceutical company Desentum Oy completed a First-in-Human clinical study last year with an immunotherapeutic h... |
| 25.10.2021 | Desentum reports positive findings for the First-in-Human clinical study of lead product candidate in birch pollen allergic adults | Desentum reports positive findings for the First-in-Human clinical study of lead product candidate in birch pollen allergic adults Mon, Oct 25, 2021 07:30 CET Desentum Oy, a clinical-stage biopharmaceutical company developing novel immunot... |
| - | Desentum | “Desentum is a biopharmaceutical company developing novel types of allergen immunotherapy products (allergy vaccines) that actually change the way the immune system reacts to allergens.” |